Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Immunology, Oncology, Antiviral, and Antiparasitic Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for DHODH drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | DHODH Recombinant Protein (WT & Mutant) >95% purity, Endotoxin <1EU/µg. Sequence Verified. FAD-binding domain intact. | View DHODH Products |
| Species Ortholog | Human, Mouse, and Plasmodium falciparum DHODH >95% purity; for selectivity and pre-tox screening. | View DHODH Products |
| Gene Delivery | DHODH Lentivirus Particles (Promise-ORF) Full-length ORF for stable mitochondrial expression. | View DHODH Products |
| Validator | DHODH siRNA Set (3 unique sequences) For specific knockdown and metabolic rescue assays. | View DHODH Products |
| Related Target A | CAD Upstream pyrimidine synthesis rate-limiting enzyme. | View CAD Products |
| Related Target B | UMPS Downstream bifunctional enzyme, pathway completion analysis. | View UMPS Products |
| Related Target C | IMPDH Purine synthesis pathway; selectivity counter-screening. | View IMPDH Products |
| Related Target D | PTEN Synergistic pathway in oncology; loss sensitizes to DHODH inhibition. | View PTEN Products |
| Related Target E | ATR DNA damage response; synergy with DHODH-induced replication stress. | View ATR Products |
Critical Assay Challenges and TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species translation (Human/Mouse/Cyno) | Ortholog proteins available >95% purity; Sequence Verified by Mass Spec. |
| Resistance profiling & mutant screening | Mutant recombinant panel covering inhibitor-binding pocket variants; Theoretical MW confirmed. |
| Off-target redox enzyme selectivity | Endotoxin-controlled (<1 EU/µg) DHODH antigen for clean IC50 determination. |
| Species selectivity (Human vs Parasitic) | Recombinant Human and P. falciparum DHODH available; sequence verified for off-target liability screening. |
| Mitochondrial penetration validation | Lentivirus-based stable cell lines expressing DHODH for nucleotide depletion assays. |
| Lack of knockdown controls | Sequence-verified DHODH siRNA for genetic rescue and specificity confirmation. |
Live DHODH R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for DHODH therapeutics is bifurcating across established immunology franchises, next-generation oncology programs, and emerging antiparasitic applications. First-generation inhibitors (teriflunomide, leflunomide) have validated the target in autoimmune indications (MS, RA). The current wave of R&D is focused on highly selective inhibitors for acute myeloid leukemia (AML) and solid tumors, with combination strategies pairing DHODH blockade with BCL-2, MEK, or ATR inhibitors entering early stages. In parallel, antiparasitic programs targeting Plasmodium falciparum DHODH (e.g., DSM265 analogs) aim to leverage species-specific structural differences for selective killing. Emerging modalities such as PROTAC degraders are being explored for refractory cancers where sustained pyrimidine depletion is needed. Resistance mutation profiling (e.g., T192M in PfDHODH) and species selectivity screening are becoming essential to manage mitochondrial toxicity and ensure therapeutic window.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor (Autoimmune) | Sanofi (Teriflunomide), Generics | Multiple Sclerosis, Rheumatoid Arthritis | Selectivity profiling; need pure target vs off-target panels. |
| Small Molecule Inhibitor (Oncology) | Bayer, Immunic, ASLAN Pharma, Salarius | AML, Solid Tumors, IBD | Enzyme kinetics (IC50/Ki) with purified active DHODH; mitochondrial permeability cell assays. |
| Antiparasitic Agent | Medicines for Malaria Venture (MMV) | Malaria, Toxoplasmosis | Species selectivity panels (Human vs Plasmodium DHODH) to minimize host toxicity. |
| PROTAC / Degrader | Various Biotechs | Refractory Cancers | Degradation assays; need specific antibodies for Western Blot/Flow. |
| Immunomodulator | Sanofi (legacy), Various | RA, Psoriasis | Cellular proliferation rescue assays with defined nucleotide pools. |